ReNetX Bio has an immediate opening for a Chief Medical Officer responsible  advancing the company’s lead development molecule AXER-204 in clinical development as a treatment for chronic spinal cord injury.

The Chief Medical Officer for ReNetX Bio will possess an extensive track record of advancing clinical trials successfully. With a background in Neurology or other relevant specialty, the successful candidate will demonstrate a robust knowledge of Protocol
design, experience in working with Key Opinion Leaders and overseeing, implementation, and execution of successful clinical trials.​